Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy

被引：14
作者：
Barth, T. [1 ]
Zeman, F. [2 ]
Helbig, H. [1 ]
Gamulescu, M. -A. [1 ]
机构：
[1] Univ Med Ctr Regensburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany
[2] Univ Med Ctr Regensburg, Ctr Clin Studies ZKS, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany
来源：
INTERNATIONAL OPHTHALMOLOGY | 2018年 / 38卷 / 03期
关键词：
Choroidal neovascularization; Punctate inner choroidopathy; Intravitreal antiangiogenic therapy; Anti-VEGF (vascular endothelial growth factor); OCULAR HISTOPLASMOSIS; PHOTODYNAMIC THERAPY; SURGICAL-MANAGEMENT; CLINICAL-FEATURES; CASE SERIES; BEVACIZUMAB; RANIBIZUMAB; RESOLUTION;
D O I：
10.1007/s10792-017-0536-0
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections. Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed. Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1-9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6-40 months). BCVA improved in eight eyes (mean Delta +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Delta -4.3 lines). CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.
引用
收藏
页码：923 / 931
页数：9
相关论文
共 32 条
[1]  
Amaro Miguel Hage, 2007, Arq. Bras. Oftalmol., V70, P577, DOI 10.1590/S0004-27492007000400003
[2]   Punctate Inner Choroidopathy [J].
Amer, Radgonde ;
Lois, Noemi .
SURVEY OF OPHTHALMOLOGY, 2011, 56 (01) :36-53
[3]   INTRAVITREAL BEVACIZUMAB FOR INFLAMMATORY CHOROIDAL NEOVASCULARIZATION Results from the Pan-American Collaborative Retina Study Group at 24 Months [J].
Arevalo, J. Fernando ;
Adan, Alfredo ;
Berrocal, Maria H. ;
Espinoza, Juan V. ;
Maia, Mauricio ;
Wu, Lihteh ;
Roca, Jose A. ;
Quiroz-Mercado, Hugo ;
Ruiz-Moreno, Jose M. ;
Serrano, Martin A. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (02) :353-363
[4]   Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome [J].
Brown, J ;
Folk, JC ;
Reddy, CV ;
Kimura, AE .
OPHTHALMOLOGY, 1996, 103 (07) :1100-1105
[5]   Resolution of punctate inner choroidopathy lesions with oral prednisone therapy [J].
Brueggeman, RM ;
Noffke, AS ;
Jampol, LM .
ARCHIVES OF OPHTHALMOLOGY, 2002, 120 (07) :996-996
[6]  
Campos Joana, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P76
[7]   Punctate Inner Choroidopathy: A Clinical Case Report [J].
Campos, Joana ;
Campos, Antonio ;
Beselga, Diana ;
Mendes, Silvia ;
Neves, Arminda ;
Castro Sousa, J. P. .
CASE REPORTS IN OPHTHALMOLOGY, 2013, 4 (03) :155-159
[8]   Ranibizumab Treatment for Choroidal Neovascularization from Causes Other than Age-Related Macular Degeneration and Pathological Myopia [J].
Carneiro, Angela M. ;
Silva, Rufino M. ;
Veludo, Maria J. ;
Barbosa, Augusto ;
Ruiz-Moreno, Jose M. ;
Falcao, Manuel S. ;
Brandao, Elisete M. ;
Falcao-Reis, Fernando M. .
OPHTHALMOLOGICA, 2011, 225 (02) :81-88
[9]   Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin [J].
Chan, Wai-Man ;
Lai, Timothy Y. Y. ;
Liu, David T. L. ;
Lam, Dennis S. C. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (06) :977-983
[10]   Photodynamic therapy: a treatment option in choroidal neovascularisation secondary to punctate inner choroidopathy [J].
Chatterjee, S ;
Gibson, JM .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2003, 87 (07) :925-927
1234